Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Naratriptan
Drug ID BADD_D01535
Description Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.
Indications and Usage For the acute treatment of migraine attacks with or without aura in adults.
Marketing Status approved; investigational
ATC Code N02CC02
DrugBank ID DB00952
KEGG ID D08255
MeSH ID C106783
PubChem ID 4440
TTD Drug ID D0T3KI
NDC Product Code 69452-340; 69452-341; 23155-054; 42043-130; 42043-131; 23155-055; 50090-6162; 0054-0278; 0054-0279
UNII QX3KXL1ZA2
Synonyms naratriptan | N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide | GR 85548A | naratriptan hydrochloride | N-methyl-3-(1-methyl-4-piperidyl)indole-5-ethanesulfonamide monohydrochloride | 1H-indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride | Naramig | Amerge | Colatan
Chemical Information
Molecular Formula C17H25N3O2S
CAS Registry Number 121679-13-8
SMILES CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bronchitis22.07.01.001; 11.01.09.001--
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Cardiac murmur13.14.01.001--Not Available
Cerebral infarction24.04.06.002; 17.08.01.004--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest pain08.01.08.002; 02.02.02.011; 22.12.02.0030.011783%Not Available
Chills15.05.03.016; 08.01.09.001--
Cold sweat23.02.03.002; 08.01.03.0240.006733%Not Available
Colitis ischaemic24.04.08.012; 07.08.01.004--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.0010.007407%
Coordination abnormal17.02.02.004--Not Available
Cough22.02.03.001--
Cystitis20.03.02.002; 11.01.14.001--
Dehydration14.05.05.001--
Depressed level of consciousness17.02.04.002--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dissociation19.14.01.002--Not Available
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug abuse19.07.06.0100.005050%Not Available
Drug dependence19.07.06.0110.006733%Not Available
Drug ineffective08.06.01.0060.018853%Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 8 Pages